Saumen Chakraborty

Saumen Chakraborty, CFO of Dr Reddy's is confident of getting back on to the growth path starting FY18 on the back of more than 15 significant launches and approvals that will help the pharma major make a comeback.

Not worried about Trump's comments on drug pricing: Dr Reddy's

Chakraborty is pleased with the announcements for the infrastructure, manufacturing and the SMEs sectors. but he says the Budget hasn't yet met the mark on pharma and education expenditure.

New launches in H2FY17 will boost growth: Dr Reddy's

The fall in revenue and profits in the first quarter was due to lack of launches in the US, says Saumen Chakraborty, CFO of Dr Reddy‘s. The company launched its first product in the US in July.

Hope to commercialise 4 products acquired from Teva by FY18: DRL

Saumen Chakraborty, CFO of the company told CNBC-TV18 that they hope to commercialise four out of the eight products by FY18. He said all the eight products are expected to have limited competition.

Board to consider buyback of equity shares on Feb 17: Dr Reddy's

Saumen Chakraborty, President and CFO, Dr Reddy's Lab said they will be making a proposal to the board for buying back equity shares on February 17.

See huge opportunity in Venezuela; US supply not restricted: DRL

Saumen Chakraborty, CFO, Dr Reddy's, says the company has been calibrating sales in Venezuala where the market and capacity is huge.

USFDA warning: Have 15 days to respond, says DRL CFO

Saumen Chakraborty, CFO, Dr Reddy's Laboratories, says "The warning letter has come telling the management to respond within 15 working days in terms of strategy and plan."

Greece crisis not to hurt software exports: Export body

The default crisis of Greece will have marginal impact on software exports, an export promotion council official said on Thursday.

Approval for more than 60 ANDAs pending: DRL

Over the last few months there have been 5 or 6 audits. Since DRL has invested quite significantly in terms of the cultural transformation in quality area, it got some of the places zero 483 which is uncommon, says CFO Saumen Chakraborty.

Dr Reddy's hopes to keep margins, despite high R&D cost

Dr Reddy's Laboratories is hopeful of maintaining its operating margins going ahead on the back of impending new product launches, however cautioned of higher R&D expenses going ahead.